Quantcast

Latest B-cell chronic lymphocytic leukemia Stories

2014-02-20 16:25:31

Company launches its first product, IMBRUVICA(TM), and records net product revenue of $13.6 million SUNNYVALE, Calif., Feb. 20, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013. Financial Results for the Quarter and Year Ended December 31, 2013 Revenue Total revenue for the quarter ended December 31, 2013 increased 113% to $123.6 million, from $58.0 million for the...

2014-02-20 12:02:02

Babies who develop leukemia during the first year of life appear to inherit an unfortunate combination of genetic variations that can make the infants highly susceptible to the disease, according to a new study at Washington University School of Medicine in St. Louis and the University of Minnesota. The research is available online in the journal Leukemia. Doctors have long puzzled over why it is that babies just a few months old sometimes develop cancer. As infants, they have not lived...

2014-02-13 12:27:27

FLINT, Mich., Feb. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today that IMBRUVICA(TM) (ibrutinib) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic lymphocytic lymphoma (CLL) in patients who have received at least one prior therapy. An improvement in survival or disease-related symptoms has not been established. IMBRUVICA(TM), a Bruton's tyrosine kinase (BTK) inhibitor, is an oral...

2014-02-12 16:26:29

CLL is second indication approved by FDA for ibrutinib; previously approved for mantle cell lymphoma patients WHITE PLAINS, N.Y., Feb. 12, 2014 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of ibrutinib to treat patients with chronic lymphocytic leukemia (CLL) is a significant advance for patients with this blood cancer. Ibrutinib received FDA approval in November to treat patients with mantle cell lymphoma (MCL) who had previously been treated with one...

2014-02-12 16:25:59

HORSHAM, Pa., Feb. 12, 2014 /PRNewswire/ -- Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA(TM) (ibrutinib) capsules for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) IMBRUVICA was first approved in November 2013 for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.(1) Both indications are based...

2014-02-12 12:32:40

SUNNYVALE, Calif., Feb. 12, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA((TM)) (ibrutinib) as a single agent for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.(1) This indication is based on overall response rate (ORR). An improvement in survival or disease-related symptoms has not been established.(1) IMBRUVICA is the first...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-24 11:25:34

Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy Use of a twice-daily pill could turn a deadly blood cancer into a highly treatable disease, according to scientists at Weill Cornell Medical College who led a multinational research team. Their findings on the therapy for chronic lymphocytic leukemia (CLL), reported in the Jan. 22 issue of the New England Journal of Medicine, suggest that patients may be able to avoid having to take debilitating...

2014-01-07 12:27:02

RARITAN, N.J., Jan. 7, 2014 /PRNewswire/ -- Janssen Research & Development, LLC today announced the early stopping of PCYC-1112-CA, the Phase 3 study of IMBRUVICA(TM) (ibrutinib) in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), based on the recommendation of an Independent Data Monitoring Committee (IDMC), which concluded that the study showed a significant difference in progression-free survival (PFS) as compared to the control, the...

2014-01-07 12:26:56

SUNNYVALE, Calif., Jan. 7, 2014 /PRNewswire/ -- Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that an Independent Data Monitoring Committee (IDMC) unanimously recommended that the Phase III RESONATE study, PCYC-1112-CA, a head-to-head comparison of IMBRUVICA(TM) (ibrutinib) versus ofatumumab, be stopped early because the primary and a key secondary endpoint of the study have been met. At the planned interim analysis, the Phase III RESONATE study demonstrated that IMBRUVICA showed...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related